高级检索
当前位置: 首页 > 详情页

Cancer-associated fibroblasts: overview, progress, challenges, and directions

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Kunming Med Univ, Yanan Hosp, Dept Urol, Kunming, Yunnan, Peoples R China [2]Kunming Med Univ, Yanan Hosp, Dept Gen Surg, Kunming, Yunnan, Peoples R China [3]Kunming Med Univ, Affiliated Hosp 2, Dept Urol, Kunming, Yunnan, Peoples R China [4]First Peoples Hosp Yunnan Prov, Xinkunhua Hosp, Dept Med Qual Management, Kunming, Yunnan, Peoples R China [5]Kunming Med Univ, Yanan Hosp, Dept Sci Res, Kunming, Yunnan, Peoples R China
出处:
ISSN:

摘要:
Tumors are one of the main causes of death in humans. The development of safe and effective methods for early diagnosis and treatment of tumors is a difficult problem that needs to be solved urgently. It is well established that the occurrence of tumors involves complex biological mechanisms, and the tumor microenvironment (TME) plays an important role in regulating the biological behavior of tumors. Cancer-associated fibroblasts (CAFs) are a group of activated fibroblasts with significant heterogeneity and plasticity in the tumor microenvironment. They secrete a variety of active factors to regulate tumor occurrence, development, metastasis, and therapeutic resistance. Although most studies suggest that CAFs have significant tumor-promoting functions, some evidence indicates that they may have certain tumor-suppressive functions in the early stage of tumors. Current research on CAFs continues to face many challenges, and the heterogeneity of their origin, phenotype, and function is a major difficulty and hot spot. To provide new perspectives for the research on CAFs and tumor diagnosis and treatment, this review summarizes the definition, origin, biomarkers, generation mechanism, functions, heterogeneity, plasticity, subpopulations, pre-metastasis niches (PMN), immune microenvironment, and targeted therapy of CAFs, describes the research progress and challenges, and proposes possible future research directions based on existing reports.

基金:

基金编号: 82060536 2017DG004-04 2020J0218 2020-SW-12

语种:
高被引:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 2 区 生物工程与应用微生物 2 区 遗传学 2 区 医学:研究与实验 3 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 2 区 生物工程与应用微生物 3 区 遗传学 3 区 医学:研究与实验 4 区 肿瘤学
JCR分区:
出版当年[2020]版:
Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 GENETICS & HEREDITY Q2 ONCOLOGY
最新[2023]版:
Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 GENETICS & HEREDITY Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Kunming Med Univ, Yanan Hosp, Dept Urol, Kunming, Yunnan, Peoples R China [2]Kunming Med Univ, Yanan Hosp, Dept Gen Surg, Kunming, Yunnan, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82493 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号